RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $145 Price Target

Benzinga · 06/02 15:40
RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $145 price target.